ArticleTherapeutic advances in medical oncology2025

A phase Ib/II trial of neoadjuvant neratinib added to standard therapy in patients with HER2-positive or HR-positive/HER2-negative inflammatory breast cancer (including stage III and IV disease).

Bora Lim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.